Neovacs Balance Sheet Health
Financial Health criteria checks 4/6
Neovacs has a total shareholder equity of €47.5M and total debt of €650.6K, which brings its debt-to-equity ratio to 1.4%. Its total assets and total liabilities are €52.6M and €5.0M respectively.
Key information
1.4%
Debt to equity ratio
€650.59k
Debt
| Interest coverage ratio | n/a |
| Cash | €887.09k |
| Equity | €47.53m |
| Total liabilities | €5.03m |
| Total assets | €52.56m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 0W8U's short term assets (€3.8M) exceed its short term liabilities (€3.0M).
Long Term Liabilities: 0W8U's short term assets (€3.8M) exceed its long term liabilities (€2.0M).
Debt to Equity History and Analysis
Debt Level: 0W8U has more cash than its total debt.
Reducing Debt: 0W8U's debt to equity ratio has reduced from 2.7% to 1.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 0W8U has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: 0W8U has less than a year of cash runway if free cash flow continues to grow at historical rates of 18.1% each year.